期刊
TRANSPLANTATION
卷 106, 期 11, 页码 2122-2136出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/TP.0000000000004163
关键词
-
资金
- Instituto de Salud Carlos III - European Union [PI19/01360, INT20/00061, CB06/04/0065]
Liver transplantation is the only cure for end-stage liver disease, but the limited availability of donor organs and increasing number of potential recipients pose challenges. The use of MELD and MELDNa to prioritize patients on the waiting list has resulted in reduced mortality, but concerns have been raised about their accuracy due to changing recipient profiles. This review provides a comprehensive evaluation of the advantages, limitations, and potential alternatives to MELD and MELDNa, as well as future options for increasing the donor pool and improving donor-recipient matching.
Liver transplantation is the only curative treatment for end-stage liver disease. Unfortunately, the scarcity of donor organs and the increasing pool of potential recipients limit access to this life-saving procedure. Allocation should account for medical and ethical factors, ensuring equal access to transplantation regardless of recipient's gender, race, religion, or income. Based on their short-term prognosis prediction, model for end-stage liver disease (MELD) and MELD sodium (MELDNa) have been widely used to prioritize patients on the waiting list for liver transplantation resulting in a significant decrease in waiting list mortality/removal. Recent concern has been raised regarding the prognostic accuracy of MELD and MELDNa due, in part, to changes in recipients' profile such as body mass index, comorbidities, and general condition, including nutritional status and cause of liver disease, among others. This review aims to provide a comprehensive view of the current state of MELD and MELDNa advantages and limitations and promising alternatives. Finally, it will explore future options to increase the donor pool and improve donor-recipient matching.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据